To the Editors: Although commendable, Winston and colleagues' evaluation of the utility of fluconazole prophylaxis among patients with acute leukemia seems overly enthusiastic (1) . Perfect (2) has suggested six criteria for justifying antifungal prophylaxis: safety, efficacy, cost, consequence, prevalence, and resistance. Based on these criteria, fluconazole does not show clear benefits in this study. No difference was observed in the incidence of invasive fungal infections, the most important measure of efficacy. There was a decrease in the rate of superficial fungal infections among fluconazole recipients (6%; 95% CI, 2% to 17%) when compared with placebo recipients (15%); fluconazole recipients also experienced a delay in the time before initiation of empiric amphotericin. Oropharyngeal and cutaneous candidal infections, however, respond rapidly to treatment. Moreover, because clotrimazole or nystatin were not routinely used, the study may not have been effectively blinded, as the presence of thrush may have influenced the decision to begin empiric amphotericin B. Determining whether the cost of fluconazole prophylaxis was justified by other savings is not possible without data on length of hospitalization. Consequences were not influenced, as shown by the 90-day mortality rate of 21% in fluconazole recipients compared with 18% in placebo recipients.
The inability to show a major benefit may be due to the relatively low prevalence of invasive fungal infections among patients with acute leukemia (8% in this study) compared with bone marrow transplant recipients (3), among whom fluconazole prophylaxis led to a clinically significant decrease in invasive fungal infections. Colonization with resistant fungi and yeasts did not emerge during this study; however, the study involved 256 patients at 18 institutions. Reports of the emergence of C. krusei infections associated with fluconazole use have come from prolonged observation at single institutions (4, 5) and may reflect selection pressure on the hospital flora.
The routine use of prophylactic fluconazole in patients with acute leukemia of average risk is not supported by this study. It is possible that a subgroup of patients with leukemia, such as those with very prolonged neutropenia, might benefit from fluconazole prophylaxis. Physicians who use fluconazole prophylaxis should continue to use early empiric amphotericin for unexplained fevers in patients with neutropenia.
Kaiser H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-51. 4 In response: In our multicenter trial (1) involving 257 patients, we did not observe a significant increase in the incidence of colonization or infection by either C. krusei or T. glabrata in patients with acute leukemia who were receiving prophylactic fluconazole (400 mg/d). Similar results were found in the randomized, placebo-controlled trial of prophylactic fluconazole in 357 patients undergoing bone marrow transplantation (2) . The single case report and two small clinical trials of low-dose prophylactic fluconazole (50 or 200 mg/d) referred to by Drs. Akiyama, Sakamaki, and Onozawa also did not prove that prophylactic fluconazole enhances the risk for infection or colonization by these organisms (3) (4) (5) . Nevertheless, in vitro susceptibility tests indicate that C. krusei and T. glabrata isolates are frequently resistant to fluconazole. Thus, we agree that prophylactic fluconazole cannot be relied on for preventing infection by either C. krusei or T. glabrata. Single cases or uncontrolled, retrospective studies of patients receiving lowdose prophylactic fluconazole (200 mg/d) such as that of Akiyama and coworkers cannot tell us to what degree fluconazole prophylaxis increases the risk for colonization or infection. Well-controlled clinical trials of large numbers of patients given adequate doses of prophylactic fluconazole are necessary.
We disagree with the analysis by Drs. Pavia and Riley. We neither expressed enthusiasm nor made recommendations regarding the use of prophylactic fluconazole or empiric amphotericin B. Instead, we reported certain benefits (decreased colonization and infection by Candida species other than C. krusei, good safety profile, and no observed increase in infection or colonization by resistant isolates) and limitations (no reduction in amphotericin use or overall mortality) of prophylactic fluconazole in patients with acute leukemia. We also found a lower probability of invasive fungal infection in fluconazole recipients compared with placebo recipients among patients not receiving empiric amphotericin B (P = 0.03; see our Figure 3 [1]). We encourage physicians to carefully assess all our results in making decisions about whether to use prophylactic fluconazole.
Drew J. Winston, MD
UCLA Medical Center Los Angeles, CA 90024-1678
Histamine-2-Receptor Antagonists and Serum Ethanol Levels
To the Editors: I agree with the conclusions of Raufman and colleagues (1) that drugs such as cimetidine and ranitidine that t Variability in mean serum ethanol concentration reflects differences among subjects. Testing for a statistically significant difference between peak serum and peak breath ethanol requires an evaluation of withinsubject differences.
t These results presumably reflect the estimated concentrations in whole blood, although they are reported in the article (1) as the peak breath ethanol concentration.
are used to suppress the production of gastric acid do not influence the serum ethanol concentrations reached after moderate alcohol consumption. This is true when alcohol is consumed on an empty stomach as well as after a meal (2) . Accordingly, this drug-alcohol interaction, the subject of unprecedented news media attention, lacks any clinical or medicolegal relevance (3).
However, their inclusion of breath alcohol measurements raised concerns about their analysis. As shown in Table 1 , peak serum ethanol concentrations reported by Raufman and colleagues are approximately 7% to 17% lower than the values estimated by breath analysis. Breath ethanol levels are always approximately 2000 times lower than the coexisting concentration in an equal volume of blood (4) .
Furthermore, breath alcohol devices such as the Lion Alcolmeter S-D2 (MPD, Inc., Owensboro, Kentucky) are calibrated with NALCO (MPD, Inc.) alcohol-gas standards to give an estimate of the alcohol concentration in venous whole blood and not in serum. It is widely known that the ethanol concentrations in plasma or serum are about 10% to 20% higher than those in an equal volume of whole blood because of the different amounts of water in these biofluids (5) . I believe this discrepancy may be explained by inaccurate calibration of the breath alcohol analyzer or an arithmetic error in translating the instrument readings into serum ethanol levels (mmol/L).
Nonetheless, because the same breath-alcohol analyzer was used to test patients receiving all treatments, this bias in the reported readings (Table 1) would not negate their conclusions.
A. W. Jones, PhD, DSc University Hospital 581 85 Linkoping Sweden
In response: We appreciate the comments made by Dr. Jones on our recent article (1) about the lack of interaction between histamine-2-receptor antagonists and orally ingested ethanol.
Dr. Jones is correct in noting that the breath ethanol values given in our article actually represent an estimation of blood ethanol concentration. This was clearly stated in the legend to Figure 4 : "Values determined using the Lion Alcolmeter actually represent blood ethanol concentrations." We felt that referring to these values as breath ethanol, rather than blood ethanol, would be less confusing for most readers.
Dr. Jones suggests that "error" may account for the higher values obtained using the breath analyzer compared with those obtained using gas chromatography. We believe these differences reflect well-known methodologic problems associated with breath analyzers that have been previously reported by Dr. Jones (2) . In our study, ethanol was given orally, in contrast to those in which ethanol was administered intravenously. Thus, despite extensive rinsing of the mouth and pharynx, it is certainly possible that residual oral ethanol contributed to the slightly higher readings observed with the breath analyzers. It is for these reasons that our conclusions were based on data obtained from head-space gas chromatographic measurements of ethanol concentration. Nevertheless, as Dr. Jones points out, it is evident from our study that regardless of the method used to measure ethanol, there is no clinically important interaction between ethanol and histamine-2 blockers. 
Jean-Pierre

Sleep Apnea and the Risk for Perioperative Myocardial Infarction
To the Editors: The article by Ashton and colleagues (1) focused on the stratification of patients before noncardiac surgery in order to estimate the risk for perioperative myocardial infarction. Surprisingly, given the large number of patients (1487 men older than 40 years), they did not report a single case of obstructive sleep apnea, which is a risk factor for ischemic heart disease (2, 3). Assuming a 1% prevalence of this syndrome in the general population (the lower limit of the many reported epidemiologic studies) (4), at least 15 patients might have had the syndrome before the intervention. We suggest that some patients who had perioperative myocardial infarction in that study had the obstructive sleep apnea syndrome, and their airway obstruction worsened because of the use of hypnotics and narcotics (5) . Appropriate diagnosis and treatment with nasally administered continuous positive airway pressure in the recovery room might have partly prevented the myocardial infarctions. Preoperative cardiac risk assessment should include questions about snoring and daytime hypersomnolence, as well as polysomnographic studies in symptomatic and high-risk patients (mainly those who are obese or hypertensive). In patients with the obstructive sleep apnea syndrome, studies are needed to confirm that continuous positive airway pressure has value in the perioperative period.
Louis Dominguez Ortega, MD Daniel Carnevali-Ruiz, MD Elena Diaz Gallego Complutense University Madrid
Snain
In response: The prevalence of obstructive sleep apnea appears to be greater among men with a history of ischemic heart disease (1). The existence of a causal link between obstructive sleep apnea and myocardial ischemia (in men with preexisting coronary artery disease) or between obstructive sleep apnea and the development of coronary atherosclerosis has not been established; the alternative is that obstructive sleep apnea is a proxy for an as-yet-unknown causal factor. Nevertheless, as Dr. Ortega and colleagues point out, it is reasonable to assume that a man with coexisting sleep apnea syndrome and coronary artery disease might be at a higher risk for perioperative myocardial infarction with noncardiac surgery than a man with only coronary artery disease. This is because recovery room respiratory depression induced by analgesics and residual anesthetics might exacerbate the gas exchange and the hemodynamic aberrations associated with sleep apnea.
We cannot provide data on the prevalence of obstructive sleep apnea among the 1487 men in our study. Our preoperative interview did not include screening questions to detect undiagnosed sleep apnea. However, the letter by Dr. Ortega and colleagues prompted us to go back and examine the records of the men who had perioperative myocardial infarction in our study. Preoperatively, none was known to have sleep apnea, but we found that 1 patient, a diabetic patient with heart failure, was diagnosed with sleep apnea 7 days after his below-knee amputation. This man was 5'8" tall and weighed 240 pounds. He was referred for polysomnography by his surgeons, who noted that he had apneic episodes in the recovery room. His infarction was diagnosed on postoperative day 5; his only symptom was lethargy.
We agree with Dr. Ortega and colleagues that screening questions about snoring and daytime hypersomnolence should be added to the preoperative medical evaluation, especially in obese patients. Women should also be questioned, because they have a higher prevalence of sleep apnea than previously recognized. Young and colleagues (2) found the malerfemale ratio for sleep apnea to be 3:1 instead of 8:1 or 10:1 as was previously believed. More data are needed to determine the extent to which sleep apnea increases perioperative mortality and morbidity. 
Isolating Borrelia burgdorferi from Erythema Migrans
To the Editors: Erythema migrans can mimic other circular, erythematous eruptions. The isolation of Borrelia burgdorferi from erythema migrans can establish the diagnosis of Lyme disease (1); 86% of skin biopsy cultures of erythema migrans lesions were reported to grow B. burgdorferi (2) . However, biopsies are time-consuming, expensive, and more invasive than needle aspiration. Recently, a double-needle cutaneous lavage of saline was found to be slightly less sensitive than skin biopsy, but because of the discomfort of saline injection, xylocaine anesthesia was required (3) .
From June to September in 1991 and 1992, a single needle was used to aspirate erythema migrans lesions. Ten patients were identified with probable erythema migrans (circular erythema >5 cm) from among outpatients with "outdoor" exposures. Nine cases of erythema migrans had been reported in the hyperendemic Lyme disease area north of La Crosse, Wisconsin (4), and four patients were recently bitten by Ixodes dammini. Five patients had primary erythema migrans, and five had early disseminated Lyme disease (multiple erythema migrans).
The lesions were disinfected with alcohol, which was allowed to dry. A small amount of subcutaneous tissue fluid was aspirated with three back-and-forth passes beneath the edge of erythema migrans lesions using an 18-or 20-gauge needle on a 3-mL syringe. Saline was not injected. The same needle and syringe were then immediately flushed with 1 to 2 mL of fresh BSK-II media. After 34 °C incubation, dark-field microscopy was done weekly for 4 weeks.
Five aspirates showed B. burgdorferi (confirmed by direct fluorescence antibody). Two positive cultures required 0.45-jum filtration to remove contaminating bacteria (5) . At the time of aspiration, Lyme titers, tested by enzyme immunoassay and immunofluorescent assay were positive for IgM antibodies in four of seven patients.
Although other techniques for culturing erythema migrans lesions have similar sensitivities, a single-needle aspiration is quick, inexpensive, and easily done.
William A. Agger, MD Gundersen Clinic La Crosse, WI 54601
The Missing Macroglobulin
We recently had a patient with Waldenstrom macroglobulinemia whose diagnosis was delayed because the automated blood analyzer did not detect the macroglobulin.
A 49-year-old man had experienced epistaxis, dyspnea, and weakness for several months. His sclerae were icteric and pale, and he had retinal hemorrhages as well as marked tortuosity and dilatation of the retinal veins. The liver and spleen were not palpable and he had no peripheral lymphadenopathy.
A peripheral smear showed marked erythrocyte rouleaux and plasmacytoid lymphocytes. Serum protein electrophoresis showed a striking gamma spike (Figure 1) , and immunofixation electrophoresis showed a monoclonal IgM-K. His bone marrow was replaced with mature and plasmacytoid lymphocytes. Serum viscosity was 8.3 (normal, <2.0). The Sia test result was strongly positive and the precipitate plummeted to the bottom of the tube; this finding was described by Waldenstrom (1) as typical of an IgM euglobulin. Electrophoresis of the waterdiluted serum showed that the paraprotein was missing because the euglobulin had precipitated (Figure 1 ). Electrophoresis of the serum euglobulin precipitate showed that it was the monoclonal IgM (Figure 1) .
Using the Miles-Technicon Dax 48 (Miles, Inc., West Ha- ven, Connecticut), the chemistry laboratory reported his total serum protein concentration as 1.2, 1.7, and 0.6 g/dL, respectively, on the first 3 days after admission, whereas we obtained a refractometric estimate of 11.3 g/dL. The manufacturer recommended distilled water as the blank reagent to determine the total serum protein concentration. When the patient's serum was added to the water blank reagent, a heavy white precipitate formed, causing most of the total protein to be obscured. After we brought this problem to the attention of the manufacturer, they changed their recommendation to using 0.9% saline as the blank reagent for the total protein concentration. However, even after we made that change, the Dax 48 showed a total protein concentration of 5.2 g/dL, whereas the refractometric estimate was 11.1 g/dL. This continuing problem was caused by the initial dilution of all serum specimens to 1:2.5 with distilled water. If the total protein exceeds 10 g/dL (or if the concentration of another analyte is abnormally high), then, according to the manufacturer, the serum must be further diluted to 1:5.0 with distilled water. At this dilution rate, most of the euglobulin precipitated (Figure 1) . Therefore, the MilesTechnicon Dax 48 provides a falsely low estimate of serum total protein concentration if the specimen has a high concentration of protein, some of which is a water-insoluble euglobulin.
Christine Lawrence, MD Joseph Furgiuele, MD Albert Einstein College of Medicine Bronx, NY 10461
Thrombolytic Therapy for Acute Myocardial Infarction in Actively Menstruating Women
To the Editors: The use of systemic thrombolytic agents is widely accepted as standard therapy for acute myocardial infarction. A history of active bleeding is appropriately considered a contraindication, and many clinicians equate menstrual bleeding with "active bleeding." However, because most clinical trials have excluded women of childbearing age, the use of thrombolytic agents during menstruation has not been clearly defined. We report the successful use of systemic thrombolytic therapy in an actively menstruating woman with acute myocardial infarction.
A 43-year-old woman came to the emergency room with a 4-hour history of chest pain, and an electrocardiogram showed evidence of an acute inferior myocardial infarction. Direct coronary angioplasty was not an immediate treatment option because the only available weekend catheterization laboratory was busy with another acute interventional case. To avoid a further delay in possible reperfusion, intravenous recombinant tissue-type plasminogen activator (rt-PA) was administered, along with intravenous heparin and oral aspirin. No contraindications to thrombolytic therapy were initially identified. However, shortly after beginning therapy with rt-PA, the patient reported that she had been menstruating more heavily than usual for the past 3 days. The emergency room physician immediately stopped the rt-PA and notified the cardiologist. Given the continuing unavailability of the interventional laboratory, completion of the rt-PA regimen was recommended. The patient became pain-free within 30 minutes of restarting rt-PA therapy, with resolution of her acute electrocardiographic changes. Her creatine kinase peaked at 603 IU/L (normal, 37 to 289 IU) with a positive CK-MB isoenzyme fraction (9.2%). Her hemoglobin fell slightly on hospital day 2 from 14.8 g/dL to 13.0 g/dL, and she reported less menstrual bleeding than normal. Her menstrual bleeding stopped by day 3 without problems, and she had a stable hemoglobin of 12.8 g/dL. Cardiac catheterization before discharge showed mild inferolateral hypokinesis and two-vessel coronary disease for which successful multivessel angioplasty was done.
Our report suggests that actively menstruating women with acute myocardial infarctions can be successfully treated with rt-PA without significant bleeding complications. Previous limited use of thrombolytic agents in menstruating women also tends to support their safety (1) (2) (3) (4) (5) . This may be explained physiologically by the fact that menstrual bleeding is more of a "sloughing" process induced by a prostaglandin-mediated vasospastic response than a true form of thrombus-dependent active bleeding. However, before widespread recommendations regarding thrombolytic therapy in this subgroup of patients can be made, more data from future clinical trials are warranted.
Worsening of Neurocardiogenic Syncope by Beta-BIockers
To the Editors: Upright tilt test alone (1, 2) or in conjunction with the administration of exogenous catecholamines (3) has been used to provoke neurocardiogenic syncope in patients for whom beta-adrenergic blockers have been recommended as first-line treatment. We describe a patient with neurocardiogenic syncope in whom beta-adrenergic blockade increased the frequency of syncope and caused prolonged asystole on repeat head-up tilt test.
A 37-year-old white man had a 30-year history of recurrent presyncope and syncope that occurred once or twice a year. After 20 minutes of head-up tilt at a 60-degree angle, the patient developed nausea, started yawning, and lost consciousness. The heart rate dropped to 60 beats/min, and his blood pressure was barely palpable (Figure 1 ). These abnormalities resolved immediately after supine position was restored.
The patient took atenolol, 100 mg/d and had five episodes of syncope in the next 4 weeks. He underwent a repeat upright tilt test while receiving atenolol. After 2 minutes of tilt, the patient became nauseated and lost consciousness. The heart rate had decreased to 15 beats/min followed by complete asystole lasting 31 seconds (Figure 1 ). During this time, no blood pressure was palpable and he had no spontaneous respiration. The patient regained consciousness spontaneously after being restored to the supine position. Atenolol therapy was discontinued, and disopyramide, 750 mg daily, was started. A repeat tilt test during disopyramide therapy did not show any abnormality. He has had no recurrent symptoms in 6 months of follow-up.
The patient had neurocardiogenic syncope with a paradoxical response to beta-blocker therapy. Dangovian and colleagues (4) also described a patient with neurocardiogenic syn- cope in whom a 25-second asystole occurred during follow-up tilt on metoprolol, 100 mg/d. However, metoprolol did not increase the frequency of spontaneous syncope. The mechanism by which beta-blocker therapy may worsen the neurocardiogenic syncope is unknown. Conceivably, episodes of neurocardiogenic syncope are not always triggered by transient adrenergic surges, and a relative central hypovolemia may be of greater pathophysiologic significance in some patients. In such instances, pretreatment with beta-blockers may blunt an otherwise protective reflex sinus tachycardia; thus, the cardioinhibitory and vasodepressor reflex worsens.
Mayer Y. Rashtian, MD
Los Angeles County-University of Southern California Medical Center Los Angeles, CA 90017
Marked Elevation of Prostate-Specific Antigen after Prolonged Prostatic Trauma
To the Editors: Prostate-specific antigen (PSA), a glycoprotein produced by prostatic epithelial cells with low individual and no circadian variability, is increased in benign prostatic hypertrophy and prostatic carcinoma (1) . Elevations greater than 10.0 ng/dL have been correlated with the presence of prostate cancer (specificity approaching 92%) (2) . I describe the occurrence of a marked, although transient, increase in the PSA level in association with moderately severe, continuous prostatic trauma.
A 66-year-old man with diabetes and essential hypertension was treated with nifedipine, glyburide, and aspirin. In July 1992, physical examination showed a slightly enlarged prostate gland (40 g) without nodules. The PSA level was 2.9 ng/dL. On 8 September, he saw a urologist for frequency, dysuria, and perineal discomfort after a 70-mile ride in a small skiff in bad weather, during which he sustained repeated severe perineal trauma. His prostate felt slightly boggy, but prostatic secretions and urinalysis were normal. The PSA level was 76 ng/dL, with the same result on re-examination of that sample a week later. On 21 October, the PSA level was 2.7 ng/dL. On 16 November, examination showed a slightly enlarged, nontender prostate; the PSA level was 2.8 ng/dL; results of rectal examination and the PSA level have remained unchanged through April 1993.
Increases in the PSA level have been reported with severe trauma (surgery) and in 25% of patients after biopsy (3). The PSA level has not been reported to increase with digital examination (4) or rectal ultrasound (3), although a minor increase lasting less than 24 hours has been reported with massage (5).
In our patient, continued trauma to the prostate gland may have caused breakdown of normal gland architecture, facilitating diffusion of large amounts of PSA into the circulation. A careful history for possible prostatic trauma is warranted when unexpected elevation of the PSA is encountered. To the Editors: We share Dr. Stolley's concerns about the inadequacy of nonrandomized studies to identify and evaluate reliably the effects of experimental drugs. Our experience, however, is entirely inconsistent with his premise that there exists a "trend toward abandonment of randomization in large community-based trials" (1) .
The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), sponsored by the National Institute of Allergy and Infectious Diseases, was developed specifically to afford community practitioners the opportunity to participate in randomized trials. This program, initiated in 1989, has been extremely successful; 20 studies are in progress or have been completed in community settings; only 4 of the studies were nonrandomized because of the observational nature of the study design. Some of these randomized trials were planned to enroll upward of a 1000 patients; one about-to-be-initiated trial comparing the strategies of early and late combination antiretroviral therapy may be the largest trial of therapy for human immunodeficiency virus infection ever conducted. Most of these trials have been received with great enthusiasm; many have completed enrollment more rapidly than was projected.
Our observation is that treatment research in the community setting is of an increasingly randomized nature, contrary to Dr. Stolley's assertion. The ComPACT 1 study of immediate and delayed antiretroviral therapy, sponsored by the Community Consortium in the San Francisco Bay Area, is another large randomized trial, and it is assessing a question that is of heightened importance in light of the recent Concorde study in Europe (2) . The expanded access programs developed by pharmaceutical companies to run in parallel with more rigorous trials are being implemented as randomized dose-comparison studies (3) .
Patients and community activists are highly knowledgeable about the state of the art of therapy for HIV infection and AIDS, and they are more sophisticated about clinical research methods (and particularly clinical trial design) than many physicians. They increasingly appreciate the need for unbiased assessments of treatment efficacy and for pragmatic but reliable evaluation of optimal treatment strategies, and they well understand that compassion and scientific rigor are not inherently incompatible (4).
In response: We appreciate the thoughtful comments of Dr. Ginier and colleagues. We agree that absence of seasonal variation in the complication rate does not prove that alterations in dietary intake of these foods cannot cause fluctuations in the PTR. However, in geographic locations where these vegetables are available year-round, patients would need to drastically alter their intake for other reasons to induce wide swings in anticoagulation control. We have observed occasional instances of this phenomenon, but our study suggests that other factors are more important causes of variability in the PTR.
We also do not discount the potential for other medications to interfere with anticoagulation control. We were, however, quite encouraged by the results of our study, which indicate that when patients are carefully managed, as they were in our participating clinics, this is uncommon. In large part, this was probably due to the fact that patients in all the clinics were usually instructed to begin no new medications from any source without first checking with the anticoagulation clinic. We do not suppose that these results can be generalized to institutions where patients are being managed without a protocol and by inexperienced practitioners.
Although one study showed that warfarin anticoagulation can be managed safely, warfarin remains a drug with the potential for serious complications. Patients receiving this medication require extensive education and meticulous management. In large institutions, this can usually be accomplished most effectively and efficiently in a dedicated anticoagulation clinic operating within accepted guidelines (1 
